Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China

Nature Medicine

Volumn 26, Issue 4, 2020, Pages 506-510

  Wu, Joseph T ^a   Leung, Kathy ^a   Bushman, Mary ^b   Kishore, Nishant ^b   Niehus, Rene ^b   de Salazar, Pablo M ^b   Cowling, Benjamin J ^a   Lipsitch, Marc ^b   Leung, Gabriel M ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; ARTICLE; CASE FATALITY RATE; CHINA; CONTROLLED STUDY; CORONAVIRUS DISEASE 2019; FEMALE; HUMAN; INFECTIOUS AGENT; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PROBABILITY; PUBLIC HEALTH; REMISSION; RISK ASSESSMENT; ADOLESCENT; AGED; ASYMPTOMATIC DISEASE; BETACORONAVIRUS; CHILD; COMPLICATION; CORONAVIRUS INFECTION; INFANT; LABORATORY TECHNIQUE; MIDDLE AGED; MORTALITY; PANDEMIC; PRESCHOOL CHILD; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; VERY ELDERLY; VIRUS PNEUMONIA;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ASYMPTOMATIC DISEASES; BETACORONAVIRUS; CHILD; CHILD, PRESCHOOL; CHINA; CLINICAL LABORATORY TECHNIQUES; CORONAVIRUS INFECTIONS; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; MODELS, STATISTICAL; MORTALITY; PANDEMICS; PNEUMONIA, VIRAL; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 85082809072     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/s41591-020-0822-7     Document Type: Article

References (32)

1. Ghani, A. et al. Methods for estimating the case fatality ratio for a novel, emerging infectious disease. Am. J. Epidemiol. 162, 479–486 (2005).
2. Wong, J. Y. et al. Case fatality risk of influenza A (H1N1pdm09): a systematic review. Epidemiology 24, 830–841 (2013).
3. Yu, H. et al. Human infection with avian influenza A H7N9 virus: an assessment of clinical severity. Lancet 382, 138–145 (2013).
4. Wu, J. T., Leung, K. & Leung, G. M. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet (2020); 10.1016/S0140-6736(20)30260-9
5. Liu, Y., Eggo, R. M. & Kucharski, A. J. Secondary attack rate and superspreading events for SARS-CoV-2. Lancet (2020); 10.1016/S0140-6736(20)30462-1
6. World Health Organization. Report of the WHO–China Joint Mission on Coronavirus Disease 2019 (COVID-19), 16–24 February 2020 (2020); https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf
7. Li, Q.et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N. Eng. J. Med. (2020); 10.1056/NEJMoa2001316
8. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)—China. China CDC Weekly 2, 113–122 (2020).
9. Chinese Center for Disease Control and Prevention. Dashboard of Reported 2019-nCoV Cases (2020); http://2019ncov.chinacdc.cn/2019-nCoV/
10. Data Platform of Shanghai Observer. Line List of 2019-nCoV Confirmed Fatal Cases (from publicly available information) (2020); http://data.shobserver.com/www/index.html#/home
11. Wuhan Municipal Health Commission. Wuhan Municipal Health Commission’s Briefing on the Current Pneumonia Epidemic in the City (2020); http://wjw.wuhan.gov.cn/
12. Hubei Municipal Health Commission. Hubei Municipal Health Commission’s Briefing on the Current Pneumonia Epidemic in the Province (2020); http://wjw.hubei.gov.cn/fbjd/dtyw/
13. Wong, J. Y. et al. Infection fatality risk of the pandemic A(H1N1)2009 virus in Hong Kong. Am. J. Epidemiol. 177, 834–840 (2013).
14. Zou, L. et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N. Eng. J. Med. (2020); 10.1056/NEJMc2001737
15. Pan, Y., Zhang, D., Yang, P., Poon, L. L. M. & Wang, Q. Viral load of SARS-CoV-2 in clinical samples. Lancet Inf. Dis. (2020); 10.1016/S1473-3099(20)30113-4
16. Callaway, E. Time to use the p-word? Coronavirus enters dangerous new phase. Nature (2020); https://www.nature.com/articles/d41586-020-00551-1
17. Niehus, R., De Salazar, P. M., Taylor, A. & Lipsitch, M. Quantifying bias of COVID-19 prevalence and severity estimates in Wuhan, China that depend on reported cases in international travelers. Preprint at medRxiv https://doi.org/10.1101/2020.02.13.20022707 (2020).
18. The State Council of The People’s Republic of China. Press Conference of the Joint Prevention and Control Mechanism of the State Coucil (2020); http://www.gov.cn/xinwen/2020-02/09/content_5476513.htm
19. National Health Commission of People’s Republic of China. Notice of the General Office of the National Health Commission on the Distribution of the Plan of Prevention and Control of the Pneumonia Caused by the Novel Coronavirus (Version 4) (2020); http://www.gov.cn/zhengce/zhengceku/2020-02/07/content_5475813.htm
20. Hubei Municipal Health Commission. Situation of the Epidemic of Pneumonia caused by the Novel Coronavirus in Hubei, as of Feb 12 (2020); http://wjw.hubei.gov.cn/fbjd/dtyw/202002/t20200213_2025581.shtml
21. Jia, N. et al. Case fatality of SARS in mainland China and associated risk factors. Tropical Med. Int. Health 14, 21–27 (2009).
22. Donnelly, C. A. et al. Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. Lancet 361, 1761–1766 (2003).
23. Leung, G. M. et al. The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: an analysis of all 1755 patients. Ann. Intern. Med. 141, 662–673 (2004).
24. Lau, E. H. et al. A comparative epidemiologic analysis of SARS in Hong Kong, Beijing and Taiwan. BMC Infect. Dis. 10, 50 (2010).
25. Taubenberger, J. K. & Morens, D. M. 1918 influenza: the mother of all pandemics. Rev. Biomed. 17, 69–79 (2006).
26. Collins, S. D. Age and sex incidence of influenza in the epidemic of 1943–44, with comparative data for preceding outbreaks: based on surveys in Baltimore and other communities in the Eastern States. Public Health Rep. (1896–1970) 59, 1483–1503 (1944).
27. Andreasen, V., Viboud, C. & Simonsen, L. Epidemiologic characterization of the 1918 influenza pandemic summer wave in Copenhagen: implications for pandemic control strategies. J. Inf. Dis. 197, 270–278 (2008).
28. Donaldson, L. J. et al. Mortality from pandemic A/H1N1 2009 influenza in England: public health surveillance study. BMJ 339, b5213 (2009).
29. Oh, M. D. et al. Middle East respiratory syndrome: what we learned from the 2015 outbreak in the Republic of Korea. Korean J. Intern. Med. 33, 233–246 (2018).
30. Wong, J. Y. et al. Hospitalization fatality risk of influenza A (H1N1)pdm09: a systematic review and meta-analysis. Am. J. Epidemiol. 182, 294–301 (2015).
31. Abbad, A. et al. Middle East respiratory syndrome coronavirus (MERS-CoV) neutralising antibodies in a high-risk human population, Morocco, November 2017 to January 2018. Euro. Surveill. 24, 1900244 (2019).
32. Backer, J. A., Klinkenberg, D. & Wallinga, J. Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20–28 January 2020. Euro. Surveill. 25, 2000062 (2020).